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species level and for providing new 
data about the emergence or reemer-
gence of rickettsioses, as reported 
here. These assays are, however, time-
consuming and only available in spe-
cialized reference laboratories. 
Clinicians need to be aware of the 
presence murine typhus in Algeria, es-
pecially among patients with unspecif-
ic signs and fever of unknown origin. 
Tetracyclines remain the treatment of 
choice. 
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Natural Co-infec-
tion with 2 Parvovi-
rus Variants in Dog 
To the Editor: Canine parvovirus 
(CPV) emerged in the late 1970s, pre-
sumably by mutations in feline pan-
leukopenia virus, and became a major 
viral pathogen of dogs worldwide (1). 
Between 1979 and 1981, the original 
type 2 virus (CPV-2) was replaced by 
a new genetic and antigenic variant, 
type 2a (CPV-2a). Between 1983 and 
1984, CPV-2a was replaced by type 
2b (CPV-2b), which differs from type 
2a by only 1 epitope located at resi-
due 426 of the VP2 capsid protein (2). 
CPV-2 does not replicate in cats, but 
the new variants replicate in dogs and 
cats (3). Recently, an antigenic change 
has been observed in a new strain, 
CPV-2c, isolated from domestic dogs 
in Italy (4). This variant was also de-
tected in Vietnam (5), other countries 
in Europe (6), and the United States 
(7). CPV-2c was recently detected in 
cats (8) and is characterized by a re-
placement of aspartic acid with glu-
tamic acid at residue 426 of the VP2 
capsid protein.
To identify CPV types 2, 2a, and 
2b, PCR methods were developed (9). 
However, these methods could not 
distinguish type 2c from type 2b (4). 
Consequently, we used a PCR–restric-
tion fragment-length polymorphism 
(RFLP) assay with endonuclease 
MboII. This enzyme can distinguish 
type 2c from other CPVs (4). Re-
cently, a real-time PCR assay based 
on minor groove binder (MGB) probe 
technology was developed for rapid 
identifi cation and characterization of 
the antigenic variants. This assay is 
based on 1 nucleotide polymorphism 
in the VP2 gene (10).
In June 2006, a 10-week-old fe-
male dog (PT-32/07) was brought to 
the veterinary clinic in Figueira da 
Foz, Portugal, with clinical signs of 
parvovirus infection, after an episode 
of  gastrointestinal disease in her litter-
mates. Three littermates, also brought 
to the clinic, showed no signs of infec-
tion. None of the dogs were vaccinated 
against CPV. Clinical signs in dog PT-
32/07 were lethargy, anorexia, vom-
iting, diarrhea, and a temperature of 
39.3°C. Identical signs were observed 
in 1 littermate 3 days later; the 2 other 
dogs did not show any signs other than 
lethargy and loose stools. 
Rectal swab samples from all 
dogs were screened for CPV by using 
an immunomigration rapid test (Syn-
biotics Corporation, Lyon, France). 
Two of the dogs showed negative 
results, and 2 showed positive re-
sults. Feces, serum, and lingual swab 
samples were positive for parvovirus 
DNA. DNA was quantifi ed by using a 
real-time PCR with TaqMan technol-
ogy performed in an i-Cycler iQ (Bio-
Rad Laboratories, Milan, Italy).
CPV variants were characterized 
by using MGB probe technology. This 
technology uses type-specifi c probes 
labeled with different fl uorophores 
(FAM and VIC) that can detect single 
nucleotide polymorphisms between 
CPV types 2a/2b and 2b/2c (10). 
MGB probes specifi c for type 2b were 
labeled with FAM in both type 2a/2b 
678 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 4, April 2008
LETTERS
and 2b/2c assays, and MGB probes 
specifi c for type 2a (type 2a/2b assay) 
and type 2c (type 2b/2c assay) were 
labeled with VIC. 
All specimens from 1 dog (PT-
32/07) were positive for the 2 vari-
ants of CPV type 2 (CPV 2b and CPV 
2c). Conversely, of the 3 littermates, 
2 were positive for CPV type 2b and 
1 was positive for CPV type 2c in all 
samples (Table).
A conventional PCR and RFLP 
analyses were performed by using the 
method of Buonavoglia et al. (4) with 
known positive CPV-2b and CPV-2c 
samples as controls to confi rm our 
fi ndings. The 583-bp PCR product 
obtained from the coinfected dog by 
using primer pair 555for/555rev was 
digested with MboII. Digestion gener-
ated 2 fragments (≈500 and 80 bp) in 
all dog samples. The CPV-2c control 
sample showed 2 fragments (≈500 and 
80 bp), and CPV-2b control sample 
was not digested with MboII.
We report CPV-2b and CPV-2c 
variants in samples from a dog with 
littermates that were positive for 
CPV-2b or CPV-2c during an episode 
of gastrointestinal disease. Co-infec-
tion with multiple CPV variants that 
showed high genetic diversity in the 
VP2 gene has recently been reported 
in a domestic cat (8). Continuous and 
rapid evolution of CPV may cause 
serious problems in diagnostic test-
ing and vaccine effi cacy. Antigenic 
variation may negatively affect vac-
cine effi cacy if changes occur at ma-
jor antigenic sites. Thus, continuous 
monitoring for novel genetic and anti-
genic virus types is needed. Additional 
studies are in progress to characterize 
nucleotide sequences of all CPV iso-
lates from this case.
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Table. Detection by minor groove binder probe assay of CPV antigenic variants in different specimens from dogs from the same litter
(10 weeks old), Portugal, 2006* 
TaqMan probe 
Dog Vaccines
Rapid test 
result for CPV 
Days in 
clinic Clinical course Samples
FAM
a/b
FAM
b/c
VIC
a/b
VIC
b/c CPV
PT-15/07 None – 7 Recovered Feces + + – – 2b
Lingual swab + + – – 2b
Serum + + – – 2b
PT-16/07 None + 7 Recovered Feces + + – – 2b
Lingual swab + + – – 2b
Serum + + – – 2b
PT-17/07 None + 7 Recovered Feces – – – + 2c
Lingual swab – – – + 2c
Serum – – – + 2c
PT-32/07 None – 7 Recovered Feces + + – + 2b/2c
Lingual swab + + – + 2b/2c
Serum + + – + 2b/2c
*CPV, canine parvovirus. 
